# Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

> **NCT03991884** · PHASE1 · COMPLETED · sponsor: **University of Washington** · enrollment: 24 (actual)

## Conditions studied

- Recurrent B Acute Lymphoblastic Leukemia
- Recurrent B Lymphoblastic Lymphoma
- Refractory B Acute Lymphoblastic Leukemia
- Refractory B Lymphoblastic Lymphoma

## Interventions

- **DRUG:** Etoposide
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Prednisone
- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** Inotuzumab Ozogamicin

## Key facts

- **NCT ID:** NCT03991884
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-24
- **Primary completion:** 2022-10-20
- **Final completion:** 2023-06-28
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-07-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03991884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03991884, "Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03991884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*